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ABSTRACT
To date, there has been a lack of evidence-based
guidance on the frequency of visual field examinations
required to identify clinically meaningful rates of change in
glaucoma. The objective of this perspective is to provide
practical recommendations for this purpose. The primary
emphasis is on the period of time and number of
examinations required to measure various rates of change
in mean deviation (MD) with adequate statistical power.
Empirical data were used to obtain variability estimates of
MD while statistical modelling techniques derived the
required time periods to detect change with various
degrees of visual field variability. We provide the
frequency of examinations per year required to detect
different amounts of change in 2, 3 and 5 years. For
instance, three examinations per year are required to
identify an overall change in MD of 4 dB over 2 years in a
patient with average visual field variability.
Recommendations on other issues such as examination
type, strategy and quality are also made.
STATEMENT OF INTEREST
Assessment of visual field damage is the major
index of the functional impact of glaucoma with
direct relevance to quality of life measures.
1–6
Visual field change was used as a primary endpoint
for progression in the recent glaucoma trials,
7–12 and
its measurement is the cornerstone of glaucoma
management influencing therapeutic decisions.
The objective of this perspective is to provide
practical recommendations for measuring clinically
relevant rates of glaucomatous visual field progres-
sion to help identify patients at risk for visual
impairment. They focus on the frequency of
examinations required for detecting various
amounts and rates of visual field change.
STATEMENT OF NEED
In routine clinical glaucoma practice, the frequency
of visual field examinations varies significantly
13
and usually falls substantially below recommenda-
tions for maintaining minimum practice stan-
dards.
14 An unacceptable number of glaucoma
patients become visually impaired or even blind
while under care.
15–21 Several factors including over-
reliance on intraocular pressure (IOP) to measure
treatment adequacy could contribute to this
finding. Having sufficient visual field data and
analysis methods may help the ophthalmologist
deliver more targeted care resulting in better
functional outcomes.
There are three main barriers to performing
sufficiently frequent visual field examinations.
Data volume and analysis
Standard automated perimetry (SAP) generates
large volumes of data, which may be time-
consuming and difficult to interpret without
statistical software. There are no generally recom-
mended methods for usage of the analyses and
translating them to clinical practice.
Resource allocation
Financial resources allocated to perimetry are often
inadequate and vary across jurisdictions. The need
for more frequent and regular visual field examina-
tions has been poorly emphasised, perhaps because
of the lack of a strong evidence-based rationale to
monitor disease progression.
Definition of progression
While criteria for progression have been clearly
defined in clinical trials, the identical criteria may
not be applicable to clinical practice. The lack of a
definition of clinically significant progression and
how to use it practically may be a disincentive to
performing frequent examinations. In turn, clinical
decisions could be made with inadequate informa-
tion, or serious progression could be missed
because of an insufficient number of examinations.
METHOD TO MEASURE VISUAL FIELD
PROGRESSION
Standard automated perimetry (SAP) should be used
Knowledge on visual field progression in glaucoma
has come almost exclusively from SAP. Recent
clinical trials in glaucoma have used only SAP as a
primary functional endpoint, and clinical benefit
from their findings is easiest if SAP is used.
What to measure
There are several approaches to analysing visual
field progression, including event (comparison of a
follow-up examination to a baseline) and trend
(regression analyses to measure rates of change)
based methods, each with a myriad of variations.
Analyses can be subdivided into individual points,
visualfieldsectors,orthewholefield.Forthepurpose
ofsimplicityanduniversality,itisrecommendedthat
rates of change are measured in units of mean
deviation or mean defect (MD), the average point-
wise difference between a given test result and the
normal age matched reference value.
Newer forms of testing should not be performed at
the expense of SAP
It is recognised that patients can only perform a
limited number of tests during clinic visits, and the
Education
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reimbursement and other resource considerations. While tests
such as short-wavelength automated perimetry (SWAP) and
frequency-doubling technology (FDT or Matrix) perimetry can
provide additional or confirmatory evidence, they remain in the
clinical research domain. In routine clinical practice, they should
not be conducted at the expense of SAP examinations. Similarly,
new imaging techniques of the optic disc and retinal nerve fibre
(RNFL) are widely used in some clinical practices and provide
complementary information. However, they cannot substitute
perimetry as a surrogate measure of visual field change.
NUMBER AND FREQUENCY OF VISUAL FIELD EXAMINATIONS
Visual field examinations should be conducted in all glaucoma
patients and suspects. The appropriate frequency and intervals
set out below are determined by the rate of change to be
detected and measurement variability. These recommendations
specify the minimum requirements. There are many circum-
stances when the frequency of examinations should be
increased because of a higher perceived risk of functional
loss—for example, suspicion of optic disc change, inadequate
IOP control, advanced field damage, pseudoexfoliation,
increased age and morbidity in the fellow eye.
It is important to obtain sufficient number of reliable
examinations in the early follow-up to establish a good baseline
and rule out rapid progression. Clinicians should take advantage
of the more frequent appointments in the first year and, if
possible, perform a visual field examination at each visit.
Rates of MD change in most glaucoma patients vary from 0
to 22.5 dB/year, depending on the severity of disease,
treatment and population samples.
22–25 They are pragmatic
estimates of visual disability patients can suffer at given rates of
progression and baseline damage. For example, a patient with
early loss (MD=24 dB) and a rapid rate of progression (22 dB/
year) can be expected to have total visual disability (230 dB) in
13 years. In a patient with moderate loss (212 dB), that rate of
change will have the same outcome in 9 years, while slower
progression (20.2 dB/year) is unlikely to lead to blindness in
that patient’s lifetime.
The ability (statistical power) to detect a given rate of visual
field change expressed in MD/year will depend on the
variability of MD over time, the number of examinations and
the amount of change we wish to detect. Using the distribution
of standard deviations (SD) of MD from glaucoma patients in a
longitudinal study
26 (fig 1), low, moderate and high variability
are defined as an SD of 0.5, 1 and 2 dB, respectively.
The statistical power to detect various rates of MD change
(expressed as a multiple of the SD) for given numbers of
examinations is shown in fig 2. Detecting a very rapid rate (four
times the SD of MD variability) of change with 80% power
requires between four and five examinations. In other words,
such a magnitude of change will be detected four times out of
five with between four and five examinations. On the other
hand detecting a small rate of change (1/4 of the SD of MD
variability) requires 19 examinations for the same power.
In practical terms, these data can be expressed as the time
period required to detect MD deterioration of 20.5 dB/year,
21.0 dB/year and 22.0 dB/year with 80% power (table 1) with
one, two and three examinations per year. These data clearly
show that detecting rates of visual field change with certainty
generally requires many visual fields; however, larger rates of
change require fewer examinations. In a patient with rapid
progression (22 dB/year) and low variability, the time required
to detect change with 80% power is 5 years if examinations are
performed once a year, 2.5 years with two examinations per
year and as little as 1.7 years if examinations are performed
three times per year. In a more typical scenario with moderate
field progression (20.5 dB/year) and moderate variability, the
respective times to detection are 13, 6.5 and 4.3 years for one,
two and three examinations per year.
OTHER REQUIREMENTS FOR MEASURING VISUAL FIELD
PROGRESSION
Examination quality
Examination quality is important. Automatic trust in the
reliability indices produced by the software should be avoided.
Besides false-positive rates, other indices (fixation losses and
specifically false negative rates) may not accurately reflect
examination quality. Consideration should be given to other
Figure 1 Distribution of intra-individual standard deviation (SD) of MD
values in patients followed for up to 12 years.
Figure 2 Statistical power to detect a significant rate of change of MD
expressed as a function of variability (SD of the MD values) and number
of examinations.
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notes (if available), patient attention, artefacts such as lens rim
defects, poor centration, incorrect refractive correction, etc,
before including or discarding examinations to evaluate
progression. High-quality visual field examinations often
depend on perimetrists being well informed, trained and
motivated. Learning effects can sometimes be difficult to
account for, as they can be negligible, or persist over several
examinations. Generally speaking, unless there are obvious
explanations, significant improvements in the initial period of
follow-up can be attributed to learning.
Examination strategy
Visual field change should only be determined with examina-
tion strategies that estimate thresholds, such as Swedish
Interactive Thresholding Algorithm (SITA) and full threshold
bracketing strategies. The same strategy (eg, always SITA
Standard) and test pattern (eg, always 30–2 or always 24–2, and
not a mixture of, for example, 30–2 and 10–2) is always much
better for determining visual field change.
Progression software
Visual field examinations generate a considerable amount of
data. Software programs that perform objective and automated
analyses are available and should be used.
27–30 All reliable
examinations should be used in the analyses to measure
progression accurately. Decision-making based on examination
of grey-scale plots should be avoided.
CONCEPTS THAT ERRONEOUSLY HINDER THE USE OF SAP TO
MEASURE PROGRESSION
While stressing the importance of measuring visual field
progression, the evidence supporting some commonly held
views should be re-examined.
Is SAP sensitive enough?
It is often quoted that up to 50% of retinal ganglion cells
(RGCs) are lost before onset of visual field damage.
31 More
recent studies with SAP reported lesser degrees of RGC loss.
32 33
Many methodological issues regarding scaling of visual field
measurements
34 and localised losses of RGCs (which make up a
smaller proportion of overall RGC loss but are more readily
detectable by SAP
32) make SAP measurements relevant. The
sensitivity of imaging devices to identify early glaucomatous
visual field loss at a specificity of 90–95% is around 70%.
35–37 The
ability of clinicians to identify structural glaucomatous damage
is similar to that of the imaging devices.
38 39 This means that
automated or clinical evaluation of structural damage fails to
identify around 30% of eyes with established early visual field
loss.
Is detection of early visual field loss important?
Visual field loss is strongly associated with quality-of-life
measures.
1–6 Recent evidence shows that motor vehicle accidents
are significantly related to the level of SAP loss,
40–42 in spite of
patients being well within the legal visual requirements to hold
a driving licence and having only early field damage in the worse
eye.
40
Are visual field examinations difficult to perform reliably?
It is often thought that visual field examinations are difficult to
perform. This attitude can potentially transfer to ophthalmol-
ogy trainees, staff and patients. Inappropriate or inaccurate
instructions to patients can lead to anxiety and unreliable
results. For example, perimetrists and patients should be made
aware that during a typical examination, around 50% of the
stimuli are not expected to be seen. Appropriate and standar-
dised patient instructions produce reliable and usable results in
the vast majority of patients.
43 44
Can visual fields be performed with cataract and macular
degeneration?
Cataract and macular degeneration are often co-morbidities of
glaucoma. The effect of mild to moderate cataract on the visual
field can be small or even negligible,
45 46 though more advanced
cataract can have a larger impact.
47 48 While cataract can
confound the glaucomatous visual field, software to largely
remove its influence is available.
27 49 Macular degeneration will,
to a certain extent, change the appearance of central glauco-
matous visual field defects and their progression. Central visual
fields should always be corroborated with fundus examination.
Tools to aid patient fixation in automated perimetry are
available and should be used.
Can small amounts of visual field progression be detected?
The amount of visual field change that can be detected depends
on the variability and number of available examinations, as
described above. Both theoretical and empirical evidence
indicates that small amounts of clinically significant change
can be detected with an adequate number of examinations and
sufficient follow-up time.
50 51
Are other perimetric techniques more sensitive than SAP?
Recent evidence supporting the notion that perimetric techni-
ques such as SWAP and FDT perimetry are clearly more
sensitive at detecting field progression is weak.
52 53 While there is
active research in this area, it is recommended that for routine
practice, other perimetric techniques should be considered
adjunct and not be performed at the expense of SAP.
Table 1 Time period (years) required to detect various rates of MD
change with 80% power in visual fields with low, moderate and high
degrees of variability with one (a), two (b) and three (c) examination per
year
(a) 1 examination/year
Progression rate (dB/year)
Variability
Low Moderate High
20.25 13 19 30
20.5 9 13 19
21.0 6 9 13
22.0 5 6 9
(b) 2 examinations/year
Progression rate (dB/year)
Variability
Low Moderate High
20.25 6.5 8.5 15
20.5 4.5 6.5 8.5
21.0 3 4.5 6.5
22.0 2.5 3 4.5
(c) 3 examinations/year
Progression rate (dB/year)
Variability
Low Moderate High
20.25 4.3 6.3 10
20.5 3 4.3 6.3
21.0 2 3 4.3
22.0 1.7 2 3
Education
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Recent research shows weak concordance between visual field
and structural measures of progression.
26 54 In routine practice,
given a certain number of tests, it is more effective to perform
the same test more frequently than a variety different tests less
frequently. Evidence supporting earlier detection of progression
with optic disc and RNFL measurements is difficult to obtain.
26
Examination of the optic disc and RNFL is of unquestionable
importance providing additional and complementary informa-
tion about disease progression. However, if resources are
limited, modern structural tests should not be substituted for
SAP examinations if the frequency of the latter falls below
recommended levels.
Are measurements of structure more reliable because they are
objective?
Because obtaining optic disc or RNFL images does not require a
subjective response from the patient, they may be erroneously
considered ‘‘real’’ and without measurement error. However,
these measurements can vary because of many patient- and
instrument-related factors. Furthermore, the frequency of
imaging required to identify progression is comparable with
that for visual fields.
55 56 Similar to analyses of visual fields,
variability can confound the interpretation of change.
57 58
RECOMMENDATIONS
On the basis of the discussion above, we make the following
recommendations.
Perform sufficient examinations to detect change
The progression status of the patient is unknown unless there is
enough information. Table 2(a) shows the rate of MD change
corresponding to total change in MD over 2, 3 and 5 years in
visual fields with moderate variability. The frequency of
examinations per year required to detect the corresponding
amounts of MD change is shown in table 2(b).
Six visual field examinations should be performed in the first
2 years
This rules out the presence of rapid progression (22 dB/year or
worse) and establishes a good set of baseline data.
Measure the rate of visual field progression
Estimating the rate of progression is invaluable for guiding
therapeutic decisions and estimating the likelihood of visual
impairment during the patient’s lifetime. In most cases,
establishing visual field progression requires several years.
Use the same threshold test
Any analysis of progression can only be performed if the same
threshold algorithm and test pattern is used.
Pay attention to examination quality
Examinations of poor quality will likely lead to an erroneous
assessment of progression. There should not be automatic
reliance on the reliability indices. Unless there are other reasons
(such as obvious learning effects, high false-positive errors, rim
artefacts) examinations should not be removed from the
analyses.
CONCLUDING REMARKS
Detection of visual field progression requires understanding of
variability, the magnitude of change that is considered clinically
significant and the number of visual fields required to detect
this change with adequate statistical power. In addition to rates
of change, other approaches such as event-based analyses are
also available and useful in certain clinical situations. Clinical
decisions on patient management require more than a formulaic
approach based on visual field progression because risk factors
such as baseline damage, age, and IOP may have different
relative weights in driving these decisions. For this reason, these
recommendations are not a protocol, but a practical guide and
template for the examination frequency to detect different rates
and/or magnitudes of change, as well as other considerations for
the appropriate use of perimetry for detecting glaucomatous
progression.
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